NCT01105702终止2 期
Temozolomide, Bevacizumab, Lithium and Radiation Treatment for Newly Diagnosed High Grade Glioma: A Phase II Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 28
- 试验地点
- 2
- 主要终点
- Median Progression-Free Survival (PFS)
研究概览
简要总结
This pilot phase II trial studies how well giving temozolomide, bevacizumab, lithium carbonate, and radiation therapy works in treating patients with newly diagnosed high grade glioma.
详细描述
Treatment of high grade glioma (HGG) with anti-angiogenic therapy results in clinical improvement and prolonged progression-free survival (PFS). However, mant patients experience diffuse recurrence and treatment failure. This is a phase II trial testing the feasibility of adding lithium carbonate, previously shown to have anti-invasive properties in HGG, to bevacizumab and chemoradiation following surgical resection of HGG.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Newly diagnosed high grade glioma (WHO Grade III and IV)
- •Brain magnetic resonance imaging (MRI) scan with gadolinium contrast
- •Patient must have normal organ and marrow function as defined below:
- •Absolute neutrophil count >= 1,500/mm^3;
- •Platelet count >=100,000/mm^3;
- •Hemoglobin >= 10g/dL;
- •Blood urea nitrogen and serum creatinine both =< 1.5 times upper limit of normal (ULN);
- •Total bilirubin both =< 1.5 times ULN;
- •SGOT and SGPT both =< 3 times ULN;
- •Alkaline phosphatase =< 2 times ULN.
- •>=18 years of age;
- •Karnofsky Performance Score >= 70;
- •Life expectancy >= 8 weeks;
- •Negative serum or urine beta-hCG pregnancy test at screening for patients of child bearing potential;
- •Men and women with reproductive potential must agree to use an acceptable method of birth control (surgical, hormonal or double barrier, ie, condom and diaphragm) during treatment and for 6 months after completion of treatment;
- •Patient or their legal proxy must provide written informed consent prior to registration on study;
- •Residual measurable disease.
排除标准
- •Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study;
- •Prior radiation therapy to the brain;
- •Prior treatment with Chemotherapy or Targeted agent
- •Previous (within last 5 years) or current malignancies at other sites except for adequately treated basal cell or squamous cell skin cancer in situ carcinoma of the cervix;
- •(Uncontrolled High blood pressure >150/100
- •Common Terminology Criteria Adverse Event 3.0 >= Grade 2 congestive heart failure (CHF);
- •History of myocardial infarction within 6 months;
- •History of stroke within 6 months;
- •Clinically significant peripheral vascular disease;
- •Evidence of bleeding diathesis or coagulopathy;
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the first dose of bevacizumab or anticipation of need for major surgical procedure during the course of the study;
- •Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to study enrollment;
- •Urine protein/Creatinine ratio >= 2.0 at screening;
- •Serious, non-healing wound, ulcer, or bone fracture;
- •Inability to comply with study and/or follow-up procedures;
- •Glioma showing active intratumoral bleeding;
- •Patients on enzyme-inducing anti-epileptic drugs;
- •Known Positive HIV-1, hepatitis B surface antigen, or hepatitis C antibody;
- •Medications like nonsteroidal antiinflammatory drugs, antipsychotics, iodides, and angiotensin-converting enzyme inhibitor, If they are receiving them, they must have been discontinued for 7 days prior to initiating lithium;
- •Any previous cytotoxic drug therapies, excluding corticosteroids and temozolomide concurrent with radiation therapy;
- •Any known genetic cancer-susceptibility syndromes;
- •Acute infection: any active viral, bacterial, or fungal infection that requires specific therapy.
- •Active uncontrolled infection - examples include sexually transmitted disease, herpes, scrofula, malaria, etc.;
- •Fever > 101.5 degrees Fahrenheit;
- •Unstable or severe intercurrent medical conditions such as unstable angina, uncontrolled arrythmias, Crohn's disease, ulcerative colitis, psoriasis, etc.;
- •Implantation of Gliadel wafers at surgery;
- •Patients with organ allografts; and
- •Allergies to reagents used in this study.
研究组 & 干预措施
TBL/RT
Experimental
Cycle 1(One 42-day cycle)
- Temozolomide 75 mg/m^2 orally (42 consecutive days), beginning the night prior to the first radiation treatment
- Radiation within 3-5 weeks of surgery
- Bevacizumab 10mg/kg, IV, starting 29 (+3) days post surgery and every 2 weeks
Treatment Cycles 2-7 (28 days per cycle)
- Temozolomide at a dose of 150 mg/m^2 on Days 1-7
- Bevacizumab 10 mg/kg on Day 8 and Day 22
- Initiate Lithium carbonate treatment at 300 mg, orally, twice a day; dose increased every 7 days up to 600mg, orally, twice a day, to a serum lithium level of 0.8-1.2 mEq/L.
干预措施: Temozolomide (Drug)
TBL/RT
Experimental
Cycle 1(One 42-day cycle)
- Temozolomide 75 mg/m^2 orally (42 consecutive days), beginning the night prior to the first radiation treatment
- Radiation within 3-5 weeks of surgery
- Bevacizumab 10mg/kg, IV, starting 29 (+3) days post surgery and every 2 weeks
Treatment Cycles 2-7 (28 days per cycle)
- Temozolomide at a dose of 150 mg/m^2 on Days 1-7
- Bevacizumab 10 mg/kg on Day 8 and Day 22
- Initiate Lithium carbonate treatment at 300 mg, orally, twice a day; dose increased every 7 days up to 600mg, orally, twice a day, to a serum lithium level of 0.8-1.2 mEq/L.
干预措施: Bevacizumab (Drug)
TBL/RT
Experimental
Cycle 1(One 42-day cycle)
- Temozolomide 75 mg/m^2 orally (42 consecutive days), beginning the night prior to the first radiation treatment
- Radiation within 3-5 weeks of surgery
- Bevacizumab 10mg/kg, IV, starting 29 (+3) days post surgery and every 2 weeks
Treatment Cycles 2-7 (28 days per cycle)
- Temozolomide at a dose of 150 mg/m^2 on Days 1-7
- Bevacizumab 10 mg/kg on Day 8 and Day 22
- Initiate Lithium carbonate treatment at 300 mg, orally, twice a day; dose increased every 7 days up to 600mg, orally, twice a day, to a serum lithium level of 0.8-1.2 mEq/L.
干预措施: Lithium Carbonate (Drug)
TBL/RT
Experimental
Cycle 1(One 42-day cycle)
- Temozolomide 75 mg/m^2 orally (42 consecutive days), beginning the night prior to the first radiation treatment
- Radiation within 3-5 weeks of surgery
- Bevacizumab 10mg/kg, IV, starting 29 (+3) days post surgery and every 2 weeks
Treatment Cycles 2-7 (28 days per cycle)
- Temozolomide at a dose of 150 mg/m^2 on Days 1-7
- Bevacizumab 10 mg/kg on Day 8 and Day 22
- Initiate Lithium carbonate treatment at 300 mg, orally, twice a day; dose increased every 7 days up to 600mg, orally, twice a day, to a serum lithium level of 0.8-1.2 mEq/L.
干预措施: Radiation (Radiation)
结局指标
主要结局
Median Progression-Free Survival (PFS)
时间窗: Up to 50 months
PFS defined as time from date of diagnosis to most recent follow up, disease progression, or death. Disease progress defined as either clinical deterioration or radiographic progressive disease on magnetic resonance imaging (MRI) per updated response assessment in neuro-oncology criteria (Wen, et al).
次要结局
- Median Overall Survival (OS)(Up to 50 months)
- Number of Patients With Grade 3 or 4 Adverse Events(The whole time while on treatment and 30 days after the treatment)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed GliomasAnaplastic AstrocytomaGliosarcomaSpinal Cord NeoplasmGlioblastomaCentral Nervous System NeoplasmNCT00100802Children's Oncology Group118
终止
1 期
Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLCRefractory Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8NCT04081688Rutgers, The State University of New Jersey16
已完成
2 期
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed GlioblastomaAdult GlioblastomaAdult GliosarcomaNCT01062425National Cancer Institute (NCI)261
进行中（未招募）
2 期
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver CancerCombined Hepatocellular Carcinoma and CholangiocarcinomaStage III Liver CancerStage IV Liver CancerNCT05211323National Cancer Institute (NCI)4
已完成
1 期
Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS DiseaseNon Small Cell Lung CancerCNS ProgressionNCT04541407University of Colorado, Denver1